Published in J Virol on April 23, 2008
Innate immunity against HIV: a priority target for HIV prevention research. Retrovirology (2010) 1.41
Innate immune signaling induces high levels of TC-specific deaminase activity in primary monocyte-derived cells through expression of APOBEC3A isoforms. J Biol Chem (2010) 1.36
Inhibition of alpha interferon (IFN-α)-induced microRNA-122 negatively affects the anti-hepatitis B virus efficiency of IFN-α. J Virol (2012) 1.10
Interleukin-1 and tumor necrosis factor-α trigger restriction of hepatitis B virus infection via a cytidine deaminase activation-induced cytidine deaminase (AID). J Biol Chem (2013) 1.03
Human APOBEC3A isoforms translocate to the nucleus and induce DNA double strand breaks leading to cell stress and death. PLoS One (2013) 0.93
Insights into cellular factors that regulate HIV-1 replication in human cells. Biochemistry (2011) 0.92
Different modes of retrovirus restriction by human APOBEC3A and APOBEC3G in vivo. PLoS Pathog (2014) 0.87
Immune-Regulatory Events in the Clearance of HBsAg in Chronic Hepatitis B: Focuses on HLA-DP. Middle East J Dig Dis (2015) 0.81
Interferon-alpha induces high expression of APOBEC3G and STAT-1 in vitro and in vivo. Int J Mol Sci (2010) 0.81
Control of hepatitis B virus replication by interferons and Toll-like receptor signaling pathways. World J Gastroenterol (2014) 0.79
Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature (2002) 21.53
Hepatitis B virus infection--natural history and clinical consequences. N Engl J Med (2004) 10.91
Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell (2003) 9.48
Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity (1996) 8.27
An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. Genomics (2002) 7.10
Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Curr Biol (2004) 6.51
Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells. J Virol (1993) 6.11
High-level hepatitis B virus replication in transgenic mice. J Virol (1995) 5.81
Inhibition of hepatitis B virus replication by APOBEC3G. Science (2004) 5.15
CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol (2003) 4.42
HIV-1 reverse transcription. A termination step at the center of the genome. J Mol Biol (1994) 4.15
Evolution of the AID/APOBEC family of polynucleotide (deoxy)cytidine deaminases. Mol Biol Evol (2004) 3.57
APOBEC3G cytidine deaminase inhibits retrotransposition of endogenous retroviruses. Nature (2005) 3.53
Complementary function of the two catalytic domains of APOBEC3G. Virology (2005) 3.45
APOBEC3 proteins inhibit human LINE-1 retrotransposition. J Biol Chem (2006) 3.30
Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci U S A (2004) 3.16
APOBEC3A and APOBEC3B are potent inhibitors of LTR-retrotransposon function in human cells. Nucleic Acids Res (2006) 3.15
A versatile tool for conditional gene expression and knockdown. Nat Methods (2006) 2.92
Intrahepatic induction of alpha/beta interferon eliminates viral RNA-containing capsids in hepatitis B virus transgenic mice. J Virol (2000) 2.65
High-molecular-mass APOBEC3G complexes restrict Alu retrotransposition. Proc Natl Acad Sci U S A (2006) 2.54
APOBEC3 inhibits mouse mammary tumour virus replication in vivo. Nature (2007) 2.28
The DNA deaminase activity of human APOBEC3G is required for Ty1, MusD, and human immunodeficiency virus type 1 restriction. J Virol (2008) 2.21
Differential sensitivity of murine leukemia virus to APOBEC3-mediated inhibition is governed by virion exclusion. J Virol (2005) 2.20
Inhibition of hepatitis B virus replication during adenovirus and cytomegalovirus infections in transgenic mice. J Virol (1998) 2.06
Cytokine-sensitive replication of hepatitis B virus in immortalized mouse hepatocyte cultures. J Virol (2002) 2.05
Interferon-inducible expression of APOBEC3 editing enzymes in human hepatocytes and inhibition of hepatitis B virus replication. Hepatology (2006) 2.03
APOBEC-mediated interference with hepadnavirus production. Hepatology (2005) 1.82
Anti-viral protein APOBEC3G is induced by interferon-alpha stimulation in human hepatocytes. Biochem Biophys Res Commun (2006) 1.76
Selective inhibition of Alu retrotransposition by APOBEC3G. Gene (2006) 1.75
Mice deficient in APOBEC2 and APOBEC3. Mol Cell Biol (2005) 1.55
Dual inhibitory effects of APOBEC family proteins on retrotransposition of mammalian endogenous retroviruses. Nucleic Acids Res (2006) 1.53
APOBEC3G targets human T-cell leukemia virus type 1. Retrovirology (2005) 1.51
Interferon prevents formation of replication-competent hepatitis B virus RNA-containing nucleocapsids. Proc Natl Acad Sci U S A (2005) 1.47
Immunopathogenesis of hepatitis B virus infection. Immunol Cell Biol (2006) 1.47
Species-specific restriction of apobec3-mediated hypermutation. J Virol (2007) 1.46
Comment on "Inhibition of hepatitis B virus replication by APOBEC3G". Science (2004) 1.41
Transcriptional and posttranscriptional control of hepatitis B virus gene expression. Proc Natl Acad Sci U S A (2003) 1.35
STAT1-independent cell type-specific regulation of antiviral APOBEC3G by IFN-alpha. J Immunol (2006) 1.25
PGC-1alpha controls hepatitis B virus through nutritional signals. Proc Natl Acad Sci U S A (2006) 1.16
Induction of antiviral cytidine deaminases does not explain the inhibition of hepatitis B virus replication by interferons. J Virol (2007) 1.13
Non-cytolytic inhibition of hepatitis B virus replication in human hepatocytes. J Hepatol (2001) 1.09
Interferon induction by polynucleotides, modified polynucleotides, and polycarboxylates. Methods Enzymol (1981) 1.08
Liver-specific expression of interferon gamma following adenoviral gene transfer controls hepatitis B virus replication in mice. Gene Ther (2005) 0.82
Interferon induction with insolubilized polynucleotides and their preparation. Methods Enzymol (1981) 0.82
Effects of testosterone suppression on serum levels of hepatitis B surface antigen and HBV-DNA in men. Liver (1998) 0.80
Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature (2003) 13.24
Conditional suppression of cellular genes: lentivirus vector-mediated drug-inducible RNA interference. J Virol (2003) 6.21
Inhibition of hepatitis B virus replication by APOBEC3G. Science (2004) 5.15
KAP1 controls endogenous retroviruses in embryonic stem cells. Nature (2010) 4.02
Embryonic stem cell potency fluctuates with endogenous retrovirus activity. Nature (2012) 3.96
Genetic reactivation of cone photoreceptors restores visual responses in retinitis pigmentosa. Science (2010) 3.92
In embryonic stem cells, ZFP57/KAP1 recognize a methylated hexanucleotide to affect chromatin and DNA methylation of imprinting control regions. Mol Cell (2011) 3.67
A versatile tool for conditional gene expression and knockdown. Nat Methods (2006) 2.92
A switch between topological domains underlies HoxD genes collinearity in mouse limbs. Science (2013) 2.86
A single amino acid determinant governs the species-specific sensitivity of APOBEC3G to Vif action. J Biol Chem (2004) 2.79
KRAB-zinc finger proteins and KAP1 can mediate long-range transcriptional repression through heterochromatin spreading. PLoS Genet (2010) 2.44
KAP1-mediated epigenetic repression in the forebrain modulates behavioral vulnerability to stress. Neuron (2008) 2.17
APOBEC3G genetic variants and their influence on the progression to AIDS. J Virol (2004) 1.97
APOBEC3G/3F mediates intrinsic resistance of monocyte-derived dendritic cells to HIV-1 infection. J Exp Med (2006) 1.82
Role for human immunodeficiency virus type 1 membrane cholesterol in viral internalization. J Virol (2002) 1.81
Reduced frequencies of NKp30+NKp46+, CD161+, and NKG2D+ NK cells in acute HCV infection may predict viral clearance. J Hepatol (2010) 1.76
A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples. J Immunol Methods (2010) 1.71
Entry and transcription as key determinants of differences in CD4 T-cell permissiveness to human immunodeficiency virus type 1 infection. J Virol (2004) 1.68
Dynamic control of endogenous retroviruses during development. Virology (2011) 1.66
The Kruppel-associated box repressor domain can trigger de novo promoter methylation during mouse early embryogenesis. J Biol Chem (2007) 1.59
A human TRIM5alpha B30.2/SPRY domain mutant gains the ability to restrict and prematurely uncoat B-tropic murine leukemia virus. Virology (2008) 1.52
Differentiation of trophoblast giant cells and their metabolic functions are dependent on peroxisome proliferator-activated receptor beta/delta. Mol Cell Biol (2006) 1.49
Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes: new evidence for direct antiinflammatory effects of statins. Arterioscler Thromb Vasc Biol (2005) 1.49
Lentiviral vector transduction of NOD/SCID repopulating cells results in multiple vector integrations per transduced cell: risk of insertional mutagenesis. Blood (2002) 1.49
Highly efficient lentiviral vector-mediated transduction of nondividing, fully reimplantable primary hepatocytes. Mol Ther (2002) 1.46
Hide, shield and strike back: how HIV-infected cells avoid immune eradication. Nat Rev Immunol (2003) 1.45
MicroRNA-124 is a subventricular zone neuronal fate determinant. J Neurosci (2012) 1.43
Tuning silence: conditional systems for RNA interference. Nat Methods (2006) 1.41
Editing at the crossroad of innate and adaptive immunity. Science (2005) 1.40
Deficiency of ribosomal protein S19 in CD34+ cells generated by siRNA blocks erythroid development and mimics defects seen in Diamond-Blackfan anemia. Blood (2004) 1.40
Structure-function analyses point to a polynucleotide-accommodating groove essential for APOBEC3A restriction activities. J Virol (2010) 1.40
Oncogenesis following delivery of a nonprimate lentiviral gene therapy vector to fetal and neonatal mice. Mol Ther (2005) 1.38
Lentivirus-mediated RNA interference of DC-SIGN expression inhibits human immunodeficiency virus transmission from dendritic cells to T cells. J Virol (2004) 1.37
APOBEC3G-depleted resting CD4+ T cells remain refractory to HIV1 infection. PLoS One (2009) 1.37
Production and titration of lentiviral vectors. Curr Protoc Hum Genet (2007) 1.36
The innate antiretroviral factor APOBEC3G does not affect human LINE-1 retrotransposition in a cell culture assay. J Biol Chem (2004) 1.36
Characterization of APOBEC3G binding to 7SL RNA. Retrovirology (2008) 1.34
DNA damage sensors ATM, ATR, DNA-PKcs, and PARP-1 are dispensable for human immunodeficiency virus type 1 integration. J Virol (2005) 1.34
Rescue of a severe mouse model for spinal muscular atrophy by U7 snRNA-mediated splicing modulation. Hum Mol Genet (2008) 1.33
Efficient gene transfer into human primary blood lymphocytes by surface-engineered lentiviral vectors that display a T cell-activating polypeptide. Blood (2002) 1.32
TRIM28 repression of retrotransposon-based enhancers is necessary to preserve transcriptional dynamics in embryonic stem cells. Genome Res (2012) 1.29
Modalities of interleukin-7-induced human immunodeficiency virus permissiveness in quiescent T lymphocytes. J Virol (2002) 1.29
Quantitative multicolor super-resolution microscopy reveals tetherin HIV-1 interaction. PLoS Pathog (2011) 1.29
The KRAB-ZFP/KAP1 system contributes to the early embryonic establishment of site-specific DNA methylation patterns maintained during development. Cell Rep (2012) 1.28
Lentivector-mediated transfer of Bmi-1 and telomerase in muscle satellite cells yields a duchenne myoblast cell line with long-term genotypic and phenotypic stability. Hum Gene Ther (2003) 1.27
Model structure of human APOBEC3G. PLoS One (2007) 1.24
Production and titration of lentiviral vectors. Curr Protoc Neurosci (2010) 1.24
The ATM substrate KAP1 controls DNA repair in heterochromatin: regulation by HP1 proteins and serine 473/824 phosphorylation. Mol Cancer Res (2011) 1.23
De novo DNA methylation of endogenous retroviruses is shaped by KRAB-ZFPs/KAP1 and ESET. Development (2013) 1.23
Gain-of-function mutant of angiotensin II receptor, type 1A, causes hypertension and cardiovascular fibrosis in mice. J Clin Invest (2007) 1.23
Contribution of proteoglycans to human immunodeficiency virus type 1 brain invasion. J Virol (2004) 1.23
IL-7 surface-engineered lentiviral vectors promote survival and efficient gene transfer in resting primary T lymphocytes. Blood (2002) 1.21
Matrix metalloprotease inhibitors restore impaired NK cell-mediated antibody-dependent cellular cytotoxicity in human immunodeficiency virus type 1 infection. J Virol (2009) 1.21
A KRAB/KAP1-miRNA cascade regulates erythropoiesis through stage-specific control of mitophagy. Science (2013) 1.18
Production and titration of lentiviral vectors. Curr Protoc Neurosci (2006) 1.18
Harnessing HIV for therapy, basic research and biotechnology. Trends Biotechnol (2005) 1.17
Induction of antiviral cytidine deaminases does not explain the inhibition of hepatitis B virus replication by interferons. J Virol (2007) 1.13
Interfering residues narrow the spectrum of MLV restriction by human TRIM5alpha. PLoS Pathog (2007) 1.11
The integrase interactor 1 (INI1) proteins facilitate Tat-mediated human immunodeficiency virus type 1 transcription. Retrovirology (2006) 1.09
ARF1 regulates Nef-induced CD4 degradation. Curr Biol (2004) 1.06
KAP1 regulates gene networks controlling mouse B-lymphoid cell differentiation and function. Blood (2012) 1.05
Efficient transduction of primary human B lymphocytes and nondividing myeloma B cells with HIV-1-derived lentiviral vectors. Blood (2002) 1.04
Global and stage specific patterns of Krüppel-associated-box zinc finger protein gene expression in murine early embryonic cells. PLoS One (2013) 1.03
Expression of FGF-2 in neural progenitor cells enhances their potential for cellular brain repair in the rodent cortex. Brain (2007) 1.02
KAP1 regulates gene networks controlling T-cell development and responsiveness. FASEB J (2012) 1.02
The HIV-1 Nef protein and phagocyte NADPH oxidase activation. J Biol Chem (2002) 1.02
Development of cellular models for ribosomal protein S19 (RPS19)-deficient diamond-blackfan anemia using inducible expression of siRNA against RPS19. Mol Ther (2005) 1.02
Liver-specific ablation of Krüppel-associated box-associated protein 1 in mice leads to male-predominant hepatosteatosis and development of liver adenoma. Hepatology (2012) 1.01
The specificity of TRIM5 alpha-mediated restriction is influenced by its coiled-coil domain. J Virol (2010) 0.98
A gene-rich, transcriptionally active environment and the pre-deposition of repressive marks are predictive of susceptibility to KRAB/KAP1-mediated silencing. BMC Genomics (2011) 0.96
Inhibition of HIV-1 multiplication by a modified U7 snRNA inducing Tat and Rev exon skipping. J Gene Med (2007) 0.95
Treatment of acetaminophen-induced acute liver failure in the mouse with conditionally immortalized human hepatocytes. J Hepatol (2005) 0.95
MHC class I chain-related protein A shedding in chronic HIV-1 infection is associated with profound NK cell dysfunction. Virology (2010) 0.94
Genotypic features of lentivirus transgenic mice. J Virol (2008) 0.94
Inducible gene and shRNA expression in resident hematopoietic stem cells in vivo. Stem Cells (2010) 0.94
KRAB can repress lentivirus proviral transcription independently of integration site. J Biol Chem (2006) 0.94
Transepithelial transport of HIV-1 by M cells is receptor-mediated. Proc Natl Acad Sci U S A (2002) 0.94
A systematic enhancer screen using lentivector transgenesis identifies conserved and non-conserved functional elements at the Olig1 and Olig2 locus. PLoS One (2010) 0.93
Measuring in vivo protein half-life. Chem Biol (2011) 0.92
Multipotential nestin and Isl-1 positive mesenchymal stem cells isolated from human pancreatic islets. Biochem Biophys Res Commun (2006) 0.92
Lentiviral vectors interfering with virus-induced CD4 down-modulation potently block human immunodeficiency virus type 1 replication in primary lymphocytes. J Virol (2004) 0.90
Development and characterization of a triple combination gene therapy vector inhibiting HIV-1 multiplication. J Gene Med (2008) 0.89